FDA Clearance Tracker · P240012-S007
AeroPace® System
Last checked: Nov 20, 2026Latest source record: Jun 22, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 22, 2026
Approved
Time to decision
27 days
Received May 26, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P240012-S007
- Device name
- AeroPace® System
- Applicant
- Lungpacer Medical USA, Inc.
- Applicant location
- Exton, PA
- Received
- May 26, 2026
- Decided
- Jun 22, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P240012
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240012
Source documents
Other decisions for Lungpacer Medical USA, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- AeroPace® SystemBreakthroughPMA
P240012 · Decided Dec 4, 2024 · 240 days after receipt
Device type: Transvenous temporary phrenic nerve stimulator (SDL) · Anesthesiology & Respiratory
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.